LEADER 01556nam0 22003493i 450 001 VAN00292772 005 20250513013735.447 017 70$2N$a9783030873240 100 $a20250513d2021 |0itac50 ba 101 $aeng 102 $aCH 105 $a|||| ||||| 181 $ai$b e 182 $ab 183 $acr 200 1 $aSARS-CoV-2 Spike Protein Convergent Evolution$eImpact of Virus Variants on Efficacy of COVID-19 Therapeutics and Vaccines$fDaniele Focosi 210 $aCham$cSpringer$d2021 215 $aXIII, 136 p.$cill.$d24 cm 410 1$1001VAN00283529$12001 $aSpringerBriefs in Microbiology$1210 $aCham$cSpringer$d2011- 620 $aCH$dCham$3VANL001889 676 $a616.079$cImmunologia$v22 676 $a579.2$cVirologia. Virus e organismi subvirali$v22 700 1$aFocosi$bDaniele$3VANV245667$01072599 712 $aSpringer $3VANV108073$4650 801 $aIT$bSOL$c20250516$gRICA 856 4 $uhttps://link.springer.com/book/10.1007/978-3-030-87324-0$zE-book - Accesso al full-text attraverso riconoscimento IP di Ateneo, proxy e/o Shibboleth 899 $aBIBLIOTECA DEL DIPARTIMENTO DI SCIENZE E TECNOLOGIE AMBIENTALI BIOLOGICHE E FARMACEUTICHE$1IT-CE0101$2VAN17 912 $fN 912 $aVAN00292772 950 $aBIBLIOTECA DEL DIPARTIMENTO DI SCIENZE E TECNOLOGIE AMBIENTALI BIOLOGICHE E FARMACEUTICHE$d17CONS e-book 189 $e17BIB189/562 562 20250513 996 $aSARS-CoV-2 Spike Protein Convergent Evolution$92568871 997 $aUNICAMPANIA